-
Mashup Score: 20YFA Proposal Form - 26 day(s) ago
Made with Softr, the easiest way to turn your data into portals and internal tools.
Source: ccproposals.softr.appCategories: General Medicine NewsTweet
-
Mashup Score: 18Season 5, Episode 2, JOGS Article Review with Dr. Young Hong - 3 month(s) ago
Podcast Episode · SSAT Soundbites: A Podcast Series for Surgeons · 02/03/2025 · 41m
Source: podcasts.apple.comCategories: General Medicine News, Hem/OncsTweet-
Thanks to @SSATNews for opportunity to share our review paper on histotripsy technology that is a game changer in treatment of cancer. Please take a listen. @CooperHealthNJ @coopermedschool @CooperSurgery @CooperGME https://t.co/vlHaOoDz7Y
-
-
Mashup Score: 0How to Claim Your Leadership Power | Michael Timms | TED - 3 month(s) ago
When faced with challenges, do you often seek someone else to blame? Leadership expert Michael Timms shows why this instinct is counterproductive, highlighti…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
How to Claim Your Leadership Power | Michael Timms | TED https://t.co/NLX5oGruFs via @YouTube
-
-
Mashup Score: 11Unmasking Disparities in Gallbladder Cancer Outcomes in the Disaggregated Asian American Population - 8 month(s) ago
Annals of Surgical Oncology – Gallbladder cancer (GBC) is associated with a high mortality rate. Asian American (AsA) are among the fastest-growing populations in the United States, yet little is…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet-
Congrats to @kkoorag et al. on unmasking disparity of gallbladder cancer in disaggregated Asian American population. @CooperHealthNJ @AnnSurgOncol @coopermedschool @CooperSurgery @CooperGME https://t.co/Yrgqu1EpBz
-
-
Mashup Score: 10SSAT Soundbites: A Podcast Series for Surgeons: Season 4, Episode 6, JOGS Article Review with Dr. Deborah Keller on Apple Podcasts - 10 month(s) ago
Show SSAT Soundbites: A Podcast Series for Surgeons, Ep Season 4, Episode 6, JOGS Article Review with Dr. Deborah Keller – Jul 8, 2024
Source: podcasts.apple.comCategories: General Medicine News, Hem/OncsTweet-
Please check out latest podcast on role of video recording for quality improvement in surgery! @CooperHealthNJ @coopermedschool @CooperFdn @CooperSurgery @CooperGME @debby_keller @SSATNews https://t.co/XS2zvW1KV9
-
-
Mashup Score: 18Cooper offers a world-first test of newly approved melanoma therapy to be made in Philly - 1 year(s) ago
A South Jersey woman was the first in the world to receive the therapy as her first treatment for advanced melanoma. The therapy eventually will be made in Philadelphia’s Navy Yard.
Source: www.inquirer.comCategories: General Medicine News, Hem/OncsTweet-
A beautiful story of our first TIL patient for TILVANCE trial! @CooperHealthNJ @coopermedschool @CooperFdn @CooperSurgery @IovanceBio @AsianAcadSurg https://t.co/dsxJQGFuw7
-
-
Mashup Score: 54Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma | IOVANCE Biotherapeutics, Inc. - 1 year(s) ago
AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune cells that recognize and fight cancer SAN CARLOS, Calif. , Feb.
Source: ir.iovance.comCategories: General Medicine News, Hem/OncsTweet-
RT @IovanceBio: The @US_FDA has granted accelerated approval for our therapy for advanced melanoma. Learn more: https://t.co/02ZyLG8HPi
-
-
Mashup Score: 52Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma | IOVANCE Biotherapeutics, Inc. - 1 year(s) ago
AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune cells that recognize and fight cancer SAN CARLOS, Calif. , Feb.
Source: ir.iovance.comCategories: General Medicine News, Hem/OncsTweet-
RT @IovanceBio: The @US_FDA has granted accelerated approval for our therapy for advanced melanoma. Learn more: https://t.co/02ZyLG8HPi
-
-
Mashup Score: 52Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma | IOVANCE Biotherapeutics, Inc. - 1 year(s) ago
AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune cells that recognize and fight cancer SAN CARLOS, Calif. , Feb.
Source: ir.iovance.comCategories: General Medicine News, Hem/OncsTweet-
RT @IovanceBio: The @US_FDA has granted accelerated approval for our therapy for advanced melanoma. Learn more: https://t.co/02ZyLG8HPi
-
-
Mashup Score: 52Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma | IOVANCE Biotherapeutics, Inc. - 1 year(s) ago
AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune cells that recognize and fight cancer SAN CARLOS, Calif. , Feb.
Source: ir.iovance.comCategories: General Medicine News, Hem/OncsTweet-
RT @IovanceBio: The @US_FDA has granted accelerated approval for our therapy for advanced melanoma. Learn more: https://t.co/02ZyLG8HPi
-
As Chair of Education Committee of @acsYFA, I want to invite submission for the 2026 ACS Clinical Congress for YFA FACS members (under 46 yo) to submit proposals for a chance to moderate and present to raise visibility of young FACS members! https://t.co/gCVY5t3tTd